

Hans-Ulrich Demuth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8859046/publications.pdf>

Version: 2024-02-01

102
papers

4,174
citations

109264

35
h-index

118793

62
g-index

114
all docs

114
docs citations

114
times ranked

3428
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Mammalian-like type II glutaminyl cyclases in Porphyromonas gingivalis and other oral pathogenic bacteria as targets for treatment of periodontitis. Journal of Biological Chemistry, 2021, 296, 100263. | 1.6 | 9 |
| 2 | Structure and Dynamics of Meprin \hat{I}^2 in Complex with a Hydroxamate-Based Inhibitor. International Journal of Molecular Sciences, 2021, 22, 5651. | 1.8 | 7 |
| 3 | Targeting isoaspartate-modified $\hat{A}\hat{I}^2$ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. Alzheimer's Research and Therapy, 2020, 12, 149. | 3.0 | 10 |
| 4 | Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease. Biochemistry, 2020, 59, 2585-2591. | 1.2 | 11 |
| 5 | Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro. Molecules, 2020, 25, 580. | 1.7 | 53 |
| 6 | Endogenous mouse huntingtin is highly abundant in cranial nerve nuclei, co-aggregates to Abeta plaques and is induced in reactive astrocytes in a transgenic mouse model of Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 79. | 2.4 | 5 |
| 7 | P4474: CHARACTERIZATION OF A NOVEL HUMANIZED WILD-TYPE TAU EXPRESSING MOUSE MODEL IN HIGH-AMYLOID BACKGROUND OF 5XFAD MICE. Alzheimer's and Dementia, 2019, 15, P1493. | 0.4 | 0 |
| 8 | QUINT: Workflow for Quantification and Spatial Analysis of Features in Histological Images From Rodent Brain. Frontiers in Neuroinformatics, 2019, 13, 75. | 1.3 | 51 |
| 9 | Concerted action of dipeptidyl peptidase IV and glutaminyl cyclase results in formation of pyroglutamate-modified amyloid peptides in vitro. Neurochemistry International, 2018, 113, 112-119. | 1.9 | 18 |
| 10 | $\hat{A}\hat{I}^2$ oligomer eliminating compounds interfere successfully with pE $\hat{A}\hat{I}^2$ (34-42) induced motor neurodegenerative phenotype in transgenic mice. Neuropeptides, 2018, 67, 27-35. | 0.9 | 9 |
| 11 | P2056: TARGETING ISOASPARTATE-MODIFIED $\hat{A}\hat{I}^2$: A DIFFERENTIAL APPROACH OF PASSIVE IMMUNOTHERAPY. Alzheimer's and Dementia, 2018, 14, P687. | 0.4 | 0 |
| 12 | O30101: A NEW MOUSE MODEL WITH HUMANIZED WILD-TYPE TAU EXPRESSION. Alzheimer's and Dementia, 2018, 14, P1008. | 0.4 | 1 |
| 13 | Dipeptidyl-Peptidase Activity of Meprin \hat{I}^2 Links N-truncation of $\hat{A}\hat{I}^2$ with Glutaminyl Cyclase-Catalyzed pGlu- $\hat{A}\hat{I}^2$ Formation. Journal of Alzheimer's Disease, 2018, 66, 359-375. | 1.2 | 20 |
| 14 | Kallikrein-related peptidases are activators of the CC chemokine CCL14. European Journal of Immunology, 2018, 48, 1592-1594. | 1.6 | 4 |
| 15 | Comprehensive Characterization of the Pyroglutamate Amyloid- \hat{I}^2 Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. Journal of Alzheimer's Disease, 2018, 63, 115-130. | 1.2 | 10 |
| 16 | Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation. Molecules, 2018, 23, 924. | 1.7 | 14 |
| 17 | Continuous assays for meprin alpha and beta using prolyl tripeptidyl aminopeptidase (PtP) from Porphyromonas gingivalis. Analytical Biochemistry, 2018, 559, 11-16. | 1.1 | 7 |
| 18 | Recent progress in translational research on neurovascular and neurodegenerative disorders. Restorative Neurology and Neuroscience, 2017, 35, 87-103. | 0.4 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Posttranslational modification impact on the mechanism by which amyloid- β induces synaptic dysfunction. <i>EMBO Reports</i> , 2017, 18, 962-981. | 2.0 | 50 |
| 20 | Glutaminy Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease—Studies on Relation to Effective Target Occupancy. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 119-130. | 1.3 | 50 |
| 21 | Structural and functional analyses of pyroglutamate-amyloid- β -specific antibodies as a basis for Alzheimer immunotherapy. <i>Journal of Biological Chemistry</i> , 2017, 292, 12713-12724. | 1.6 | 24 |
| 22 | [P4 β 457]: N-TRUNCATED AND PYROGLUTAMATE-MODIFIED A β ACCELERATES AGGREGATION OF A β SYNUCLEIN IN VITRO. <i>Alzheimer's and Dementia</i> , 2017, 13, P1505. | 0.4 | 0 |
| 23 | N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity. <i>Bioscience Reports</i> , 2017, 37, . | 1.1 | 25 |
| 24 | Characterizing Aging, Mild Cognitive Impairment, and Dementia with Blood-Based Biomarkers and Neuropsychology. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 111-126. | 1.2 | 18 |
| 25 | Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminy Cyclase Inhibitors. <i>Marine Drugs</i> , 2016, 14, 203. | 2.2 | 50 |
| 26 | Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington's Disease: increased NPY levels and differential degradation of the NPY _{1-30}} fragment. <i>Journal of Neurochemistry</i> , 2016, 137, 820-837. | 2.1 | 17 |
| 27 | Verstärkte Fibrillen-Fragmentierung N-terminal verkürzter, Pyroglutamat-modifizierter A β -Peptide. <i>Angewandte Chemie</i> , 2016, 128, 5165-5168. | 1.6 | 6 |
| 28 | Enhanced Fibril Fragmentation of N-terminally Truncated and Pyroglutamyl-Modified A β Peptides. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 5081-5084. | 7.2 | 34 |
| 29 | P4 β 298: Meprin β is Associated with Formation of Pyroglutamate-Modified A β Peptides. <i>Alzheimer's and Dementia</i> , 2016, 12, P1147. | 0.4 | 0 |
| 30 | Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis. <i>Scientific Reports</i> , 2016, 6, 31441. | 1.6 | 25 |
| 31 | The pyroglutamate modification of toxic A β resulted new therapeutic approaches: inhibitors of glutaminy cyclase and highly specific antibodies—a status report. <i>Neurobiology of Aging</i> , 2016, 39, S18-S19. | 1.5 | 1 |
| 32 | 11th German Conference on Chemoinformatics (GCC 2015). <i>Journal of Cheminformatics</i> , 2016, 8, 18. | 2.8 | 1 |
| 33 | IsoQC (QPCTL) knock-out mice suggest differential substrate conversion by glutaminy cyclase isoenzymes. <i>Biological Chemistry</i> , 2016, 397, 45-55. | 1.2 | 23 |
| 34 | Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation. <i>Neuropeptides</i> , 2016, 57, 21-34. | 0.9 | 35 |
| 35 | QIAD assay for quantitating a compound's efficacy in elimination of toxic A β oligomers. <i>Scientific Reports</i> , 2015, 5, 13222. | 1.6 | 39 |
| 36 | Proteolytic degradation of neuropeptide Y (NPY) from head to toe: Identification of novel NPY-cleaving peptidases and potential drug interactions in CNS and Periphery. <i>Journal of Neurochemistry</i> , 2015, 135, 1019-1037. | 2.1 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid- β^2 Variants and Structural Analysis by Solution NMR Spectroscopy. <i>PLoS ONE</i> , 2015, 10, e0139710. | 1.1 | 21 |
| 38 | Structural Analysis and Aggregation Propensity of Pyroglutamate A β^2 (3-40) in Aqueous Trifluoroethanol. <i>PLoS ONE</i> , 2015, 10, e0143647. | 1.1 | 27 |
| 39 | The Proteolytic Profile of Human Cancer Procoagulant Suggests That It Promotes Cancer Metastasis at the Level of Activation Rather Than Degradation. <i>Protein Journal</i> , 2015, 34, 338-348. | 0.7 | 6 |
| 40 | Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2015, 129, 565-583. | 3.9 | 38 |
| 41 | Phosphate ions and glutaminyl cyclases catalyze the cyclization of glutaminyl residues by facilitating synchronized proton transfers. <i>Bioorganic Chemistry</i> , 2015, 60, 98-101. | 2.0 | 13 |
| 42 | An anti-pyroglutamate-3 A β^2 vaccine reduces plaques and improves cognition in APP ^{swe} /PS1 ^{E9} mice. <i>Neurobiology of Aging</i> , 2015, 36, 3187-3199. | 1.5 | 45 |
| 43 | Identification of thyrotropin-releasing hormone as hippocampal glutaminyl cyclase substrate in neurons and reactive astrocytes. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2015, 1852, 146-155. | 1.8 | 9 |
| 44 | A non-canonical function of eukaryotic elongation factor 1A1: Regulation of interleukin-6 expression. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 965-975. | 1.9 | 23 |
| 45 | Mouse strain and brain region-specific expression of the glutaminyl cyclases QC and isoQC. <i>International Journal of Developmental Neuroscience</i> , 2014, 36, 64-73. | 0.7 | 13 |
| 46 | Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid- β^2 Load and Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 385-400. | 1.2 | 90 |
| 47 | Pyroglutamate-Amyloid- β^2 and Glutaminyl Cyclase Are Colocalized with Amyloid- β^2 in Secretory Vesicles and Undergo Activity-Dependent, Regulated Secretion. <i>Neurodegenerative Diseases</i> , 2014, 14, 85-97. | 0.8 | 9 |
| 48 | O2-12-05: ALTERNATIVE BETA-SECRETASE PROCESSING GENERATES N-TERMINALLY TRUNCATED ABETA PEPTIDES IN MAMMALIAN CELLS. , 2014, 10, P192-P193. | | 0 |
| 49 | P3-128: COMBINATION OF BLOOD-BASED BIOMARKERS AND NEUROPSYCHOLOGICAL ASSESSMENT ENABLES RELIABLE CLASSIFICATION OF TESTED SUBJECTS BY CONTROLS: MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. , 2014, 10, P675-P675. | | 0 |
| 50 | P3-041: BRAIN DEPOSITION OF PYROGLUTAMATE A β^2 IN A β^2 AMYLOIDOSIS. , 2014, 10, P643-P643. | | 0 |
| 51 | O1-10-02: TOXIC PGLU-ABETA IS ENHANCED AND GLUTAMINYL CYCLASE (QC) UP-REGULATED EARLY IN ALZHEIMER'S DISEASE (AD): INHIBITORS OF QC BLOCKING PGLU-ABETA FORMATION ARE IN CLINICAL DEVELOPMENT. , 2014, 10, P149-P149. | | 1 |
| 52 | P1-077: EVIDENCE FOR INVOLVEMENT OF MEPRIN B IN FORMATION OF N-TRUNCATED AND PYROGLUTAMATE-MODIFIED (PGLU) ABETA. , 2014, 10, P331-P331. | | 0 |
| 53 | Structure-Activity Relationships of Benzimidazole-Based Glutaminyl Cyclase Inhibitors Featuring a Heteroaryl Scaffold. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6613-6625. | 2.9 | 54 |
| 54 | Glutaminyl cyclase-mediated toxicity of pyroglutamate-beta amyloid induces striatal neurodegeneration. <i>BMC Neuroscience</i> , 2013, 14, 108. | 0.8 | 22 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Inhibition of Glutamyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice. <i>International Journal of Experimental Pathology</i> , 2013, 94, 217-225. | 0.6 | 26 |
| 56 | O2-07-02: Characterization of double transgenic mice, APPSLxhQC, exhibiting enhanced pyroGlu3-beta-amyloid formation to evaluate efficacy of glutamyl cyclase (QC) inhibitors. , 2013, 9, P328-P328. | | 0 |
| 57 | Pyroglutamate-3 Amyloid- β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease-Like Transgenic Mouse Models. <i>American Journal of Pathology</i> , 2013, 183, 369-381. | 1.9 | 102 |
| 58 | Glutamyl Cyclases as Novel Targets for the Treatment of Septic Arthritis. <i>Journal of Infectious Diseases</i> , 2013, 207, 768-777. | 1.9 | 15 |
| 59 | Structure of glutamyl cyclase from <i>Drosophila melanogaster</i> in space group I4. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2013, 69, 358-361. | 0.7 | 2 |
| 60 | Role of glutamyl cyclases in thyroid carcinomas. <i>Endocrine-Related Cancer</i> , 2013, 20, 79-90. | 1.6 | 21 |
| 61 | Glutamyl Cyclases. , 2013, , 1736-1742. | | 0 |
| 62 | Proteases in the Nervous System. , 2013, , 319-371. | | 4 |
| 63 | Pyroglutamate Amyloid β 2 (A β 2) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease. <i>Journal of Biological Chemistry</i> , 2012, 287, 8154-8162. | 1.6 | 71 |
| 64 | Passive Immunization against Pyroglutamate-3 Amyloid- β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study. <i>Neurodegenerative Diseases</i> , 2012, 10, 265-270. | 0.8 | 63 |
| 65 | Structural analysis of the pyroglutamate-modified isoform of the Alzheimer's disease-related amyloid- β using NMR spectroscopy. <i>Journal of Peptide Science</i> , 2012, 18, 691-695. | 0.8 | 20 |
| 66 | Crystal Structures of Glutamyl Cyclases (QCs) from <i>Drosophila melanogaster</i> Reveal Active Site Conservation between Insect and Mammalian QCs. <i>Biochemistry</i> , 2012, 51, 7383-7392. | 1.2 | 12 |
| 67 | No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 833.e39-833.e50. | 1.5 | 32 |
| 68 | Probing Secondary Glutamyl Cyclase (QC) Inhibitor Interactions Applying an in silico Modeling/Site-Directed Mutagenesis Approach: Implications for Drug Development. <i>Chemical Biology and Drug Design</i> , 2012, 80, 937-946. | 1.5 | 15 |
| 69 | N-terminal pyroglutamate formation of A β 38 and A β 40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation. <i>Journal of Neurochemistry</i> , 2012, 121, 774-784. | 2.1 | 76 |
| 70 | Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid- β . <i>Nature</i> , 2012, 485, 651-655. | 13.7 | 369 |
| 71 | Glutamyl Cyclase Knock-out Mice Exhibit Slight Hypothyroidism but No Hypogonadism. <i>Journal of Biological Chemistry</i> , 2011, 286, 14199-14208. | 1.6 | 30 |
| 72 | Structures of Glycosylated Mammalian Glutamyl Cyclases Reveal Conformational Variability near the Active Center. <i>Biochemistry</i> , 2011, 50, 6280-6288. | 1.2 | 27 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Glutamyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-A β deposits in hippocampus via distinct cellular mechanisms. <i>Acta Neuropathologica</i> , 2011, 121, 705-719. | 3.9 | 52 |
| 74 | Heteroarylketones inhibit astroglial interleukin-6 expression via a STAT3/NF- κ B signaling pathway. <i>Journal of Neuroinflammation</i> , 2011, 8, 86. | 3.1 | 11 |
| 75 | The isoenzyme of glutamyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. <i>EMBO Molecular Medicine</i> , 2011, 3, 545-558. | 3.3 | 78 |
| 76 | Highlight: Dipeptidyl peptidase 4 and related proteins. <i>Biological Chemistry</i> , 2011, 392, 151-2. | 1.2 | 0 |
| 77 | Isolation of dipeptidyl peptidase IV (DP 4) isoforms from porcine kidney by preparative isoelectric focusing to improve crystallization. <i>Biological Chemistry</i> , 2011, 392, 665-77. | 1.2 | 5 |
| 78 | Overexpression of Glutamyl Cyclase, the Enzyme Responsible for Pyroglutamate A β Formation, Induces Behavioral Deficits, and Glutamyl Cyclase Knock-out Rescues the Behavioral Phenotype in 5XFAD Mice. <i>Journal of Biological Chemistry</i> , 2011, 286, 4454-4460. | 1.6 | 79 |
| 79 | Selective inhibition of dipeptidyl peptidase 4 by targeting a substrate-specific secondary binding site. <i>Biological Chemistry</i> , 2011, 392, 223-31. | 1.2 | 22 |
| 80 | Selective Hippocampal Neurodegeneration in Transgenic Mice Expressing Small Amounts of Truncated A β Is Induced by Pyroglutamate A β Formation. <i>Journal of Neuroscience</i> , 2011, 31, 12790-12801. | 1.7 | 90 |
| 81 | Distinct glutamyl cyclase expression in Edingerâ€“Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-A β pathology in Alzheimerâ€™s disease. <i>Acta Neuropathologica</i> , 2010, 120, 195-207. | 3.9 | 29 |
| 82 | Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model. <i>International Journal of Alzheimer's Disease</i> , 2010, 2010, 1-9. | 1.1 | 20 |
| 83 | Kinetic and structural characterization of bacterial glutamyl cyclases from <i>Zymomonas mobilis</i> and <i>Myxococcus xanthus</i> . <i>Biological Chemistry</i> , 2010, 391, 1419-28. | 1.2 | 14 |
| 84 | Intraneuronal pyroglutamate-A β 3â€“42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. <i>Acta Neuropathologica</i> , 2009, 118, 487-496. | 3.9 | 151 |
| 85 | Mammalian glutamyl cyclases and their isoenzymes have identical enzymatic characteristics. <i>FEBS Journal</i> , 2009, 276, 6522-6536. | 2.2 | 37 |
| 86 | Glutamyl Cyclases Display Significant Catalytic Proficiency for Glutamyl Substrates. <i>Biochemistry</i> , 2009, 48, 11831-11833. | 1.2 | 38 |
| 87 | Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides. <i>Biochemistry</i> , 2009, 48, 7072-7078. | 1.2 | 171 |
| 88 | Developmental expression and subcellular localization of glutamyl cyclase in mouse brain. <i>International Journal of Developmental Neuroscience</i> , 2009, 27, 825-835. | 0.7 | 31 |
| 89 | Inhibitors for Human Glutamyl Cyclase by Structure Based Design and Bioisosteric Replacement. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 7069-7080. | 2.9 | 57 |
| 90 | Glutamyl cyclase inhibition attenuates pyroglutamate A β and Alzheimer's diseaseâ€“like pathology. <i>Nature Medicine</i> , 2008, 14, 1106-1111. | 15.2 | 316 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Inhibition of glutaminyl cyclase prevents pGlu β formation after intracortical/hippocampal microinjection <i>in vivo</i> / <i>in situ</i> . <i>Journal of Neurochemistry</i> , 2008, 106, 1225-1236. | 2.1 | 67 |
| 92 | Isolation of an Isoenzyme of Human Glutaminyl Cyclase: Retention in the Golgi Complex Suggests Involvement in the Protein Maturation Machinery. <i>Journal of Molecular Biology</i> , 2008, 379, 966-980. | 2.0 | 62 |
| 93 | Amyloidogenic Processing of Amyloid Precursor Protein: Evidence of a Pivotal Role of Glutaminyl Cyclase in Generation of Pyroglutamate-Modified Amyloid- β . <i>Biochemistry</i> , 2008, 47, 7405-7413. | 1.2 | 100 |
| 94 | Isolation and Characterization of Glutaminyl Cyclases from <i>Drosophila</i> : Evidence for Enzyme Forms with Different Subcellular Localization. <i>Biochemistry</i> , 2007, 46, 10921-10930. | 1.2 | 22 |
| 95 | The First Potent Inhibitors for Human Glutaminyl Cyclase: Synthesis and Structure-Activity Relationship. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 664-677. | 2.9 | 81 |
| 96 | On the Seeding and Oligomerization of pGlu-Amyloid Peptides (in vitro). <i>Biochemistry</i> , 2006, 45, 12393-12399. | 1.2 | 238 |
| 97 | Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2006, 1764, 1618-1625. | 1.1 | 73 |
| 98 | Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. <i>FEBS Letters</i> , 2004, 563, 191-196. | 1.3 | 155 |
| 99 | Identification of Human Glutaminyl Cyclase as a Metalloenzyme. <i>Journal of Biological Chemistry</i> , 2003, 278, 49773-49779. | 1.6 | 78 |
| 100 | Substrate Specificity of Glutaminyl Cyclases from Plants and Animals. <i>Biological Chemistry</i> , 2003, 384, 1583-92. | 1.2 | 59 |
| 101 | Heterologous Expression and Characterization of Human Glutaminyl Cyclase: Evidence for a Disulfide Bond with Importance for Catalytic Activity. <i>Biochemistry</i> , 2002, 41, 10849-10857. | 1.2 | 58 |
| 102 | Continuous Spectrometric Assays for Glutaminyl Cyclase Activity. <i>Analytical Biochemistry</i> , 2002, 303, 49-56. | 1.1 | 50 |